Literature DB >> 24039506

How Should We Treat Depression in Patients with Cardiovascular Disease?

Ian M Kronish1, David J Krupka, Karina W Davidson.   

Abstract

Among patients with cardiovascular disease (CVD), depression is highly prevalent and is associated with worse cardiovascular prognosis and lower quality of life. Treatments for depression in CVD patients produce modest, but clinically significant reductions in depressive symptoms and show promise for improving cardiovascular prognosis. While tricyclics should generally be avoided, antidepressants from multiple other classes appear to be safe in cardiac patients. A strategy of engaging patients in choosing medications or psychotherapy and then intensifying treatment to therapeutic goal appears to be more effective at reducing depression than single mode interventions. Recommendations for screening all CVD patients for depression may be premature given increased costs associated with screening and gaps in knowledge about the risk-benefit ratio of depression treatment in mild and moderately depressed patients.

Entities:  

Year:  2012        PMID: 24039506      PMCID: PMC3771386     

Source DB:  PubMed          Journal:  Dialog Cardiovasc Med        ISSN: 1272-9949


  25 in total

1.  Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes.

Authors:  Ian M Kronish; Nina Rieckmann; Ethan A Halm; Daichi Shimbo; David Vorchheimer; Donald C Haas; Karina W Davidson
Journal:  J Gen Intern Med       Date:  2006-08-09       Impact factor: 5.128

2.  Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial.

Authors:  François Lespérance; Nancy Frasure-Smith; Diana Koszycki; Marc-André Laliberté; Louis T van Zyl; Brian Baker; John Robert Swenson; Kayhan Ghatavi; Beth L Abramson; Paul Dorian; Marie-Claude Guertin
Journal:  JAMA       Date:  2007-01-24       Impact factor: 56.272

3.  The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered.

Authors:  A H Glassman; S P Roose; J T Bigger
Journal:  JAMA       Date:  1993-05-26       Impact factor: 56.272

4.  A national survey of cardiovascular physicians' beliefs and clinical care practices when diagnosing and treating depression in patients with cardiovascular disease.

Authors:  Robert E Feinstein; Michael Blumenfield; Barbara Orlowski; William H Frishman; Simon Ovanessian
Journal:  Cardiol Rev       Date:  2006 Jul-Aug       Impact factor: 2.644

5.  Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease.

Authors:  Carmine Pizzi; Anne Wilhelmina Saskia Rutjes; Grazia Maria Costa; Fiorella Fontana; Andrea Mezzetti; Lamberto Manzoli
Journal:  Am J Cardiol       Date:  2011-01-20       Impact factor: 2.778

6.  Beta-blockers and depression after myocardial infarction: a multicenter prospective study.

Authors:  Joost P van Melle; Daniëlle E P Verbeek; Maarten P van den Berg; Johan Ormel; Marcel R van der Linde; Peter de Jonge
Journal:  J Am Coll Cardiol       Date:  2006-11-09       Impact factor: 24.094

7.  Routine screening for depression in patients with coronary heart disease never mind.

Authors:  Roy C Ziegelstein; Brett D Thombs; James C Coyne; Peter de Jonge
Journal:  J Am Coll Cardiol       Date:  2009-09-01       Impact factor: 24.094

8.  Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study--rationale, design, and methodological issues.

Authors:  James A Blumenthal; Andrew Sherwood; Sharon D Rogers; Michael A Babyak; P Murali Doraiswamy; Lana Watkins; Benson M Hoffman; Cara O'Connell; Julie J Johnson; Seema M Patidar; Robert Waugh; Alan Hinderliter
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

9.  Selective publication of antidepressant trials and its influence on apparent efficacy.

Authors:  Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

Review 10.  Psychological and pharmacological interventions for depression in patients with coronary artery disease.

Authors:  Harald Baumeister; Nico Hutter; Jürgen Bengel
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07
View more
  4 in total

1.  The Contribution of Stress and Distress to Cardiovascular Health in Adult Survivors of Childhood Cancer.

Authors:  Margaret M Lubas; Mingjuan Wang; John L Jefferies; Kirsten K Ness; Matthew J Ehrhardt; Kevin R Krull; Daniel A Mulrooney; Deo Kumar Srivastava; Rebecca M Howell; Leslie L Robison; Melissa M Hudson; Gregory T Armstrong; Tara M Brinkman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-11-24       Impact factor: 4.090

2.  Assessment of the length of sick leave in patients with ischemic heart disease.

Authors:  Nausica Català Tella; Catalina Serna Arnaiz; Jordi Real Gatius; Oriol Yuguero Torres; Leonardo Galván Santiago
Journal:  BMC Cardiovasc Disord       Date:  2017-01-18       Impact factor: 2.298

3.  Determinates of depressive disorder among adult patients with cardiovascular disease at outpatient cardiac clinic Jimma University Teaching Hospital, South West Ethiopia: cross-sectional study.

Authors:  Halima Umer; Alemayehu Negash; Mengesha Birkie; Asmare Belete
Journal:  Int J Ment Health Syst       Date:  2019-03-05

4.  Screening for depressive symptoms in cardiovascular patients at a tertiary centre in Trinidad and Tobago: investigation of correlates in the SAD CAT study.

Authors:  Naveen Seecheran; Cathy-Lee Jagdeo; Rajeev Seecheran; Valmiki Seecheran; Sangeeta Persad; Lakshmipatty Peram; Matthew Evans; Justine Edwards; Sheri Thackoorcharan; Britney Davis; Shari Davis; Barbrianna Dawkins; Anisha Dayaram; Michelle De Freitas; Tsarina Deonarinesingh; Jiovanna Dhanai; Cherelle Didier; Shastri Motilal; Nelleen Baboolal
Journal:  BMC Psychiatry       Date:  2020-10-08       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.